PTC Therapeutics PTCT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
PTC Therapeutics (PTCT) Core Market Data and Business Metrics
Latest Closing Price
$46.6Price-Earnings Ratio
-7.85Total Outstanding Shares
77.13 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
500 Warren Corporate Center Drive, Warren, NJ, 07059
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-317.95 Million |
| Net Cash Flow | $353.96 Million |
| Net Cash Flow From Operating Activities, Continuing | $-177.97 Million |
| Net Cash Flow From Financing Activities | $849.88 Million |
| Net Cash Flow, Continuing | $353.96 Million |
| Net Cash Flow From Financing Activities, Continuing | $849.88 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $0 |
| Income/Loss From Continuing Operations Before Tax | $-425.47 Million |
| Research and Development | $531.06 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Operating Income/Loss | $-134.36 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $-13.95 Million |
| Other Comprehensive Income/Loss | $-467.15 Million |
| Comprehensive Income/Loss Attributable To Parent | $-467.15 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-467.15 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Inventory | $35.67 Million |
| Other Current Assets | $1.05 Billion |
| Current Liabilities | $610.71 Million |
| Accounts Receivable | $199.98 Million |
| Other Non-current Assets | $167.14 Million |
| Accounts Payable | $13.29 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||